Site-Specific ADC Linker for Uniform Lysine Conjugation
Solution Overview
Problem
Current site-specific conjugation methods for antibody-drug conjugates (ADCs) suffer from poor uniformity and stability, affecting efficacy and pharmacokinetics due to variations in conjugation sites and number of effector molecules.
Innovation Solution
A novel linker with a piperidine sulfonyl carbamate moiety is developed to selectively couple with lysine at a defined site on the antibody light chain, ensuring high uniformity and stability of the antibody-drug conjugate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If non-site-specific conjugation methods are used to couple effector molecules to antibodies, then the conjugation process is simple and does not require antibody modification, but the number of effector molecules and conjugation sites cannot be determined, resulting in poor uniformity
Solution Approach 1:
The patent introduces a preliminary enzymatic treatment step using transglutaminase to create specific glutamine-lysine crosslinks at defined sites on the antibody light chain before effector molecule conjugation. This preliminary action establishes a controlled conjugation architecture that enables subsequent site-specific coupling, resolving the contradiction between process simplicity and conjugation uniformity by adding a targeted preparatory step rather than modifying the entire antibody structure
2Manufacturing precision
If site-specific conjugation methods are used to achieve uniform linking of effector molecules at specific sites, then conjugation uniformity is improved, but the methods often require antibody modification via antibody engineering or enzymatic coupling which may affect antibody structural stability
Solution Approach 1:
The patent uses transglutaminase as an intermediary enzyme to catalyze the formation of glutamine-lysine crosslinks between antibody light chains and a preliminary linker structure. This intermediary enzymatic action enables site-specific conjugation without requiring antibody engineering, thereby maintaining antibody structural stability while achieving uniform conjugation. The enzyme acts as a mediator that facilitates precise coupling without permanent modification of the antibody's core structure
Solution Approach 2:
The patent employs mild coupling conditions with controlled pH (6.0-8.0) and temperature (4°C-37°C) parameters to maintain antibody structural stability during the conjugation process. By optimizing these physical parameters, the method achieves site-specific conjugation uniformity while preventing denaturation or aggregation of the antibody protein, thus resolving the contradiction between precision and stability
3Ease of manufacture
If existing coupling linkers (WO 2012/007896 A1, WO 2013/173392 A1) are used to couple to light chain lysine, then some coupling capability is achieved, but poor uniformity and insufficient site-specific conjugation proportions are observed
Solution Approach 1:
The patent introduces a locally optimized linker structure containing a piperidine sulfonyl carbamate moiety with specific spatial and electronic properties that preferentially interact with lysine residues at defined sites on the antibody light chain. This local structural optimization at the conjugation interface enhances site-specific recognition and coupling efficiency, achieving superior uniformity (over 80% site-specific conjugation) compared to existing linkers while maintaining ease of manufacture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The efficacy and efficacy of antibody-drug conjugates are enhanced through the use of a novel linker that achieves high uniformity and stability, improving pharmacokinetics and reducing variations in conjugation sites.
Implementation Method 1
comprising a piperidine sulfonyl carbamate moiety capable of selectively coupling with lysine at a defined site on the antibody light chain
Data Source
Figure 1~2
Figure 3~4
AI summary
The present invention relates to a chemical coupling linker, and an antibody-drug conjugate prepared with the linker. The present invention further relates to a use of the antibody-drug conjugate in treating related disease of tumors, etc.
